Treatment of cerebellar ataxia with 5-HT1A agonist

Cerebellum

Volumn 4, Issue 3, 2005, Pages 211-215

  Takei, Asako ^a   Hamada, Takeshi ^a   Yabe, Ichiro ^b   Sasaki, Hidenao ^b  

^a Hokuyukai Neurology Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

5 HT1A agonist; Ataxia; Spinocerebellar degeneration (SCD)

Indexed keywords

BUSPIRONE; SEROTONIN 1A AGONIST; TANDOSPIRONE;

ANOREXIA; CEREBELLAR ATAXIA; CEREBELLUM ATROPHY; CLINICAL TRIAL; COLD SENSATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; DRUG TOLERABILITY; EYE DISEASE; HEADACHE; HUMAN; HYPERSOMNIA; INSOMNIA; MACHADO JOSEPH DISEASE; MAJOR CLINICAL STUDY; NAUSEA; OLIVOPONTOCEREBELLAR ATROPHY; PAIN; PRIORITY JOURNAL; REVIEW; SPINOCEREBELLAR DEGENERATION; TREATMENT OUTCOME;

BUSPIRONE; CEREBELLAR ATAXIA; CLINICAL TRIALS; HUMANS; RECEPTOR, SEROTONIN, 5-HT1A; SEROTONIN AGONISTS;

EID: 25144443536     PISSN: 14734222     EISSN: 14734230     Source Type: Journal    
DOI: 10.1080/14734220500222318     Document Type: Review

References (36)

1. Waragai M, Ogawara K, Takaya Y, Hayashi M. Efficacy of TRH-T for spinocerebellar degeneration - the relation between clinical features and effect of TRH therapy. Rinsho Shinkeigaku. 1997;37:587-94. [In Japanese]
2. Kanazawa I, Satoyoshi E, Hirayama K, et al. Clinical evaluation of taltirelin hydrate (TA-0910) in patients with spinocerebellar degeneration - A multi-center double-blind comparative study with placebo. Rinsyo Iyaku. 1997; 13:4169-24. [In Japanese]
3. Fukuchi I, Asahi T, Kawashima K, Kawashima Y, Yamamura M, Matsuoka Y, Kinoshita K. Effects of Taltirelin hydrate (TA-0910), a novel thyrotropin-releasing hormone analog, on in vivo dopamine release and turnover in rat brain. Arzneimittelforschung. 1998;48:353-9.
4. Trouillas P. L-5-Hydroxytryptophan treatment in cerebellar ataxia: Clinical and etiological correlations. Mov Disord. 1990;5(Suppl. 1):6.
5. Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan. A double-blind study with quantified data processing. Arch Neurol. 1988;45:1217-22.
6. Lou JS, Goldfarb L, McShane L, Gatev P, Hallett M. Use of buspirone for treatment of cerebellar ataxia. An open-label study. Arch Neurol. 1995;52:982-8.
7. Trouillas P, Xie J, Adeleine P, et al. Buspirone, a 5-hydroxytryptamine1A agonist, is active in cerebellar ataxia. Results of a double-blind drug placebo study in patients with cerebellar cortical atrophy. Arch Neurol. 1997; 54:749-52.
8. Trouillas P, Xie J, Adeleine P. Buspirone, a serotonergic 5-HT1A agonist, is active in cerebellar ataxia. A new fact in favor of the serotonergic theory of ataxia. Prog Brain Res. 1997;114:589-99.
9. Friedman JH. Machado-Joseph disease/spinocerebellar ataxia 3 responsive to buspirone. Mov Disord. 1997;12:613-14.
10. Saito Y, Miwa S, Yamana T, Hasegawa Y, Takagi S. Clinical therapeutical trial of oral tandospirone for cerebellar ataxia. Nagoya Shiritu Byouin Kiyou. 1998;21:5-8. [In Japanese]
11. Takei A, Honma S, Kawashima A, et al. Beneficial effects of tandospirone on ataxia of a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2002;56:181-5.
12. Takei A, Fukazawa T, Hamada T, Yabe I, Tashiro K. 'Drug holiday' effects of tandospirone in a patient with Machado-Joseph disease. Psychiatry Clin Neurosci. 2003;57:607-8.
13. Takei A, Fukazawa T, Hamada T, Sohma H, Yabe I, Sasaki H, Tashiro K. Effects of tandospirone on '5-HT1A receptor-associated symptoms' in patients with Machado-Joseph disease. An open-label study. Clin Neuropharmacol. 2004;27:9-13.
14. Traber J, Glaser T. 5-HT1A-related anxiolytics. Trends Pharmacol Sci. 1987;8:432-7.
15. Parks CL, Robinson PS, Sibille E, Shenk T, Toth M. Increased anxiety of mice lacking the serotonin1A receptor. Proc Natl Acad Sci USA. 1998;95:10734-9.
16. Bjorvatn B, Fagerland S, Eid T, Ursin R. Sleep/waking effects of a selective 5-HT1A receptor agonist given systemically as well as perfused in the dorsal raphe nucleus in rats. Brain Res. 1997;770:81-8.
17. Sørensen E, Grønli J, Bjorvatn B, Bjørkum A, Ursin R. Sleep and waking following microdialysis perfusion of the selective 5-HT1A receptor antagonist p-MPPI into the dorsal raphe nucleus in the freely moving rat. Brain Res. 2001; 897:122-30.
18. Vickers SP, Clifton PG, Dourish CT. Behavioural evidence that d-fenfluramine-induced anorexia in the rat is not mediated by the 5-HT1A receptor subtype. Psychopharmacology. 1996;125:168-75.
19. Glennon RA, Lucki I. Behavioural models of serotonin receptor activation. In: Sanders-Bush E, editor. The serotonin receptors. Clifton, NJ: Humana Press; 1988. pp 253-93.
20. Lucki I. 5-HT1 receptors and behaviour. Neurosci Biobehav Rev. 1992;16:83-93.
21. Giordano J, Rogers L. Putative mechanisms of buspirone-induced antinociception in the rat. Pain. 1992;50:365-72.
22. Trouillas P, Takayanagi T, Hallett M, et al. International cooperative ataxia rating scale for pharmacological assessment of the cerebellar syndrome. The ataxia neuropharmacology committee of the world federation of neurology. J Neurol Sci. 1997;145:205-11.
23. Zung WWK. A self-rating depression scale. Arch Gen Psychiat. 1963;12:63-70.
24. Wieland S, Fischette CT, Lucki I. Effect of chronic treatments with tandospirone and imipramine on serotonin-mediated behavioral responses and monoamine receptors. Neuropharmacology. 1993;32:561-573.
25. 11C]WAY 100635. Eur J Pharmacol. 1995;283:R1-3.
26. Burnet PW, Eastwood SL, Lacey K, Harrison PJ. The distribution of 5-HT1A and 5-HT2A receptor mRNA in human brain. Brain Res. 1995;676:157-68.
27. Miquel MC, Doucet E, Riad M, Adrien J, Verge D, Hamon M. Effect of the selective lesion of serotoninergic neurons on the regional distribution of 5-HT1A receptor mRNA in the rat brain. Brain Res Mol Brain Res. 1992; 14:357-62.
28. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology. 1999;38:1083-152.
29. Maura G, Raiteri M. Serotonin 5-HT1D and 5-HT1A receptors respectively mediate inhibition of glutamate release and inhibition of cyclic GMP production in rat cerebellum in vitro. J Neurochem. 1996;66:203-09.
30. Maura G, Roccatagliata E, Ulivi M, Raiteri M. Serotonin-glutamate interaction in rat cerebellun: Involvement of 5-HT1 and 5-HT2 receptors. Eur J Pharmacol. 1988:31-8.
31. Raiteri M, Maura G, Barzizza A. Activation of presynaptic 5-hydroxytryptamine1-like receptors on glutamatergic terminals inhibits N-methyl-D Aspartate-induced cyclic GMP production in rat cerebellar slices. J Pharmacol Exp Ther. 1991; 257:1184-8.
32. Darrow EJ, Strahlendorf HK, Strahlendorf JC. Response of cerebellar Purkinje cells to serotonin and the 5-HT1A agonists 8-OH-DPAT and ipsapirone in vitro. Eur J Pharmacol. 1990;175:145-53.
33. Monte TL, Rieder CR, Tort AB, et al. Use of fluoxetine for treatment of Machado-Joseph disease: an open-label study. Acta Neurol Scand. 2003;107:207-10.
34. Bier JC, Dethy S, Hildebrand J, Jacquy J, Manto M, Martin JJ, Seeldrayers P. Effects of the oral form of ondansetron on cerebellar dysfunction. A multi-center double-blind study. J Neurol. 2003;250:693-7.
35. Drevets WC, Frank E, Price JC, et al. PET imaging of serotonin 1A receptor binding in depression. Biol Psychiatry. 1999;46:1375-87.
36. 11C]WAY- 100635: effects of depression and antidepressant treatment. Arch Gen Psychiatry. 2000;57:174-80.